Clinical Trials

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

25 enrolled

Phase 3 Active not recruiting

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

165 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT04895436 2026-02-09

ReVenG

Phase 2 Recruiting

75 enrolled

Phase 3 Active not recruiting

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT05099471 2025-11-28

VIWA-1

Phase 2 Recruiting

80 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT04161885 2025-10-06

VIALE-T

Phase 3 Terminated

465 enrolled

Phase 2 Active not recruiting

Neoplasms, Leukemia, Myeloid, Acute

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

156 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

LymphoidOther hematologic neoplasmPlasma cell

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Phase 1 Recruiting

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Phase 1 Active not recruiting

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

24 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT06450145 2024-06-10

APL

Phase NA Recruiting

15 enrolled

Tumor-Agnostic

Neoplasms

NCT04912063 2024-02-26

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

40 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT04092179 2024-01-24

ENAVEN-AML

Phase 1/2 Terminated

27 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT03873857 2023-09-01

FORTE

Completed

71 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01682616 2023-06-06

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

49 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03236857 2023-05-22

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

CNSLymphoidOther hematologic neoplasm

143 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Neuroblastoma, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02756611 2023-04-10

VENICE I

258 enrolled 27 charts

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

60 enrolled 12 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT03484520 2022-12-30

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

48 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT02141282 2022-12-19

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Phase 2 Completed

127 enrolled 17 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2 Completed

14 enrolled 19 charts

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

GastrointestinalLymphoidOther hematologic neoplasm

153 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT04509622 2022-05-05

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

14 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

182 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01328626 2022-02-23

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

222 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03441555 2022-02-01

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

36 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT03797261 2021-12-07

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

9 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

69 enrolled

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03625505 2021-09-14

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

61 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT01594229 2021-08-02

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

60 enrolled

Lymphoma, Non-Hodgkin, Neoplasms

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

8 enrolled 12 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT04274907 2021-02-11

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

2 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04274933 2020-10-29

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

4 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01969695 2019-12-19

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

11 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence

NCT02391480 2019-11-29

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cellThoracic

128 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Prostatic Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma

NCT03785184 2019-08-28

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms

NCT01969669 2017-11-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence

NCT01969682 2014-05-26

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Phase 1 Withdrawn